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Effects of Hyperglycemia and Effects of Ketosis on
Cerebral Perfusion, Cerebral Water Distribution,
and Cerebral Metabolism
Nicole Glaser,1 Catherine Ngo,2 Steven Anderson,2 Natalie Yuen,2 Alexandra Trifu,2
and Martha O’Donnell2
Diabetic ketoacidosis (DKA) may cause brain injuries in children.
The mechanisms responsible are difficult to elucidate because
DKA involves multiple metabolic derangements. We aimed to de-
termine the independent effects of hyperglycemia and ketosis on
cerebral metabolism, blood flow, and water distribution. We used
magnetic resonance spectroscopy to measure ratios of cerebral
metabolites (ATP to inorganic phosphate [Pi], phosphocreatine
[PCr] to Pi, N-acetyl aspartate [NAA] to creatine [Cr], and lactate
to Cr) and diffusion-weighted imaging and perfusion-weighted
imaging to assess cerebral water distribution (apparent diffusion
coefficient [ADC] values) and cerebral blood flow (CBF) in three
groups of juvenile rats (hyperglycemic, ketotic, and normal con-
trol). ATP-to-Pi ratio was reduced in both hyperglycemic and ke-
totic rats in comparison with controls. PCr-to-Pi ratio was reduced
in the ketotic group, and there was a trend toward reduction in
the hyperglycemic group. No significant differences were observed
in NAA-to-Cr or lactate-to-Cr ratio. Cortical ADC was reduced in
both groups (indicating brain cell swelling). Cortical CBF was
also reduced in both groups. We conclude that both hypergly-
cemia and ketosis independently cause reductions in cerebral
high-energy phosphates, CBF, and cortical ADC values. These
effects may play a role in the pathophysiology of DKA-related
brain injury. Diabetes 61:1831–1837, 2012
Cerebral injury caused by diabetic ketoacidosis(DKA) is an important complication of type 1diabetes in children. Approximately 1% of chil-dren with DKA develop severe, life-threatening
cerebral edema and cerebral injury (1). Many more chil-
dren with DKA, however, develop subtle cerebral edema,
which can be demonstrated using magnetic resonance
diffusion-weighted imaging (2). Magnetic resonance spec-
troscopy (MRS) studies in these children show metabolic
changes consistent with cerebral injury (3). Recent data
also suggest that memory deficits are common in children
with diabetes who have experienced DKA, suggesting that
subtle cerebral injury may occur frequently (4).
Despite the growing evidence that DKA frequently re-
sults in subtle brain injuries in children, relatively little is
understood about the pathophysiology of brain injury in this
setting. Interestingly, magnetic resonance data from animal
and human studies demonstrate that DKA is associated with
initial cytotoxic cerebral edema, progressing to vasogenic
edema during treatment with insulin and saline (2,5,6). In
addition, DKA has been shown to be associated with di-
minished cerebral blood flow (CBF) in animal models (5,6).
These findings are similar to those observed in hypoxic/
ischemic brain injury. Although some decline in CBF likely
results from hypocapnia and circulatory volume depletion
during DKA, it is not clear that these disturbances alone are
sufficient to cause cerebral injury. Whether other aspects
of DKA contribute to cerebral injury by augmenting the
reduction in CBF or by compromising cerebral metabolism
in other ways is therefore important to investigate. In the
current study, we aimed to determine the effects of hypo-
insulinemic hyperglycemia and hypoinsulinemic ketosis on
CBF, cerebral water distribution, and cerebral metabolism.
We hypothesized that effects of one or both of these con-
ditions might alter CBF and/or cerebral metabolism. If our
hypothesis is correct, one or both of these conditions might
predispose the brain to injury when other conditions (such
as severe hypocapnia and/or circulatory volume depletion)
are superimposed.
RESEARCH DESIGN AND METHODS
Hyperglycemia model. Juvenile rats (4–6 weeks of age) were administered an
intraperitoneal injection of streptozotocin (100 mg/kg for rats,100 g; 130 mg/kg
for rats .100 g). Rats were given unlimited access to water with 10% dextrose
(D10 W; Fisher Scientific, Santa Clara, CA) in the first 24-h period after strep-
tozotocin injection to prevent hypoglycemia and were subsequently allowed
unlimited access to tap water and standard rat chow. Twenty-four hours
after streptozotocin injection, rats were treated with subcutaneous insulin
(Novolin 70/30 insulin: 3 units daily for rats ,100 g, 4 units daily for rats
100–200 g, and 5 units daily for rats .200 g) for a period of 5 days to allow for
resolution of any nonpancreatic toxicities of streptozotocin. Urine glucose and
ketoacids (acetoacetate) were measured daily using Multistix urinalysis strips
(Bayer, Santa Clara, CA) up to and including the day of imaging. Animals
developing abnormal urine acetoacetate concentrations (above “trace” levels
on urinalysis strips: 0.5 mmol/L) at any time prior to imaging were not used for
the hyperglycemia model. Serum insulin concentrations were measured by
radioimmunoassay (Millipore Rat Insulin RIA; Millipore, Billerica, MA). One
day prior to magnetic resonance studies, rats received no insulin treatment
and drinking water was changed to D10 W to promote hyperglycemia. Both
this protocol and the protocol for the ketosis model (see below) were con-
ducted in accordance with the Animal Use and Care Guidelines issued by the
National Institutes of Health using protocols approved by the animal use and
care committee at the University of California, Davis.
Ketosis model. As in the hyperglycemia model, juvenile rats (4–6 weeks) were
used for this protocol. Rats were given a diet consisting of 50% standard rat
chow (LabDiet 5001; Commercial Chow, Richmond, IN) and 50% high-fat diet
(category no. D12492, OpenSource Diets, 60% fat; Research Diets) for a period
of 5 days. For an additional 5 days, rats consumed only the high-fat diet.
Twelve hours prior to imaging, rats were fasted and allowed access only to
tap water. Using this protocol, we were able to reliably generate ketosis
(b-hydroxybutyrate [bOHB] concentration .1.0 mmol/L, measured using Pre-
cision Xtra blood ketone test [Abbott Laboratories, Abbott Park, IL]). Rats that
failed to develop the previously specified level of ketosis were not used in the
study.
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Diffusion-weighted imaging and perfusion-weighted imaging procedures.
Rats in both groups were anesthetized using Na pentobarbital (65 mg/kg i.p.),
and then the left femoral vein and artery were cannulated with PE-50 poly-
ethylene tubing as previously described (7). The femoral vein cannula was
used for additional anesthesia as needed. The femoral artery cannula was used
for blood sampling. A heating pad with circulating water (Gaymar, Orchard
Park, NY) was used to maintain body temperature at 36.8–37.0°C throughout
surgery and magnetic resonance studies. Rats were also subjected to tracheal
intubation and ventilated (Harvard Small Animal Ventilator, Holliston, MA)
throughout surgery and magnetic resonance studies. Ventilation was done to
offset the tendency toward respiratory depression in the anesthetized rats and
to insure similarity to previous studies of rats with DKA conducted by our
group. Blood samples were taken for analysis of PCO2 and pH immediately
after intubation and the respiratory rate and tidal volume adjusted to maintain
the PCO2 level within the normal range. Magnetic resonance diffusion-weighted
spin echo images were acquired using a 7-Tesla Bruker Biospec MRS/magnetic
resonance imaging (MRI) system as previously described (7). apparent diffu-
sion coefficient (ADC) values (1026 cm2/s) were determined from 6 3 4 pixel
regions of interest for eight brain regions (six cortex and two striatum) using
Paravision 4.0 software with four gradient strengths of 5–95 mT/m. In each rat,
CBF (milliliters per 100 grams per second) was also determined, using perfusion-
weighted imaging analysis with continuous arterial spin labeling (ASL) and a
standard Bruker PERFPACK2 protocol (Bruker, Billerica, MA). ASL data were
acquired using the same field of view and slice thickness as used for diffusion-
weighted spin echo images, and the ASL regions of interest were chosen from
the 128 3 128 matrix so as to measure CBF and ADC on the same voxels (7,8).
Images from perfusion-weighted imaging were acquired in 4.37 min using
echo time (TE)/repetition time (TR) 12.77 ms/1,023 ms with a 1-s Adiabatic-
Fast-Passage labeling pulse in the presence of a 10 mT/m gradient to obtain
inversion68,515 Hz (62 cm) from the isocenter (also slice center) for control
and labeled images, respectively. T1 maps for the same voxels were also
acquired from selected rats in each treatment group to correct CBF mea-
surements for possible location- and treatment-dependent variations in T1.
MRS procedures. MRS measurements were performed in anesthetized rats in
a horizontal bore magnet (Oxford Instruments, Oxford, U.K.) using a two-
channel Biospec system (Bruker Biospin, Billerica, MA) running ParaVision
software. A double-tuned 1H/X Litz coil (Doty Scientific, Columbia, SC) was
used, where X is tunable for 23 Na or 31P. Field homogeneity was optimized by
localized shimming on 1H over a 9 3 9 3 9 mm voxel of interest (VOI). The
VOI was positioned inside the brain and selected to encompass as much of the
cortex as possible. After shimming, 31P and 1H MRS data were acquired.
31P MRS. An 8 3 8 3 8 mm VOI was centered on the shimmed volume.
Spectra were acquired in 43.2-min intervals using Bruker software for image-
selected in vivo spectroscopy (TR = 4 s, 80 signals averaged, 25-Hz line
broadening). Intracellular pH was calculated from the chemical shift of the
inorganic phosphate (Pi) peak relative to the phosphocreatine (PCr) peak,
using the equation intracellular pH = 6.7 + log [(shift 2 3.186)/(5.691 2 shift)]
(9). PCr, b-ATP, and Pi peaks were integrated using NUTS software (Acorn
NMR, Livermore, CA) and presented as ratios (ATP to Pi and PCr to Pi).
1H MRS. A 7 3 7 3 7 mm VOI was centered on the shimmed volume. Spectra
were acquired in 2.8-min intervals using Bruker software for point-resolved
spectroscopy (TR = 6,974 ms, 20 signals averaged, 2-Hz line broadening) with
chemical-shift–selective pulses and dephasing gradients to suppress water.
Cerebral 1H metabolite peaks were identified according to their chemical shifts
(10): N-acetylaspartate (NAA) (2.02 ppm), creatine (Cr) and PCr (3.0 ppm),
lactate (1.38 ppm), and bOHB (1.15 ppm). With a TE of 132 ms, the lipid peak
was suppressed, and the lactate and bOHB appeared as inverted peaks. The
NAA, Cr, lactate, and bOHB peaks were integrated using NUTS software and
presented as ratios (NAA to Cr, lactate to Cr, and bOHB to Cr).
Statistical analyses.Differences in MRI andMRSmeasures and differences in
insulin levels among the three groups (hyperglycemia, ketosis, and control)
were evaluated using ANOVA with Scheffe test used post hoc to detect dif-
ferences between specific pairs of groups. Differences in MRI measures among
rats that did and did not have evidence of mild nephrotoxicity from strepto-
zotocin injection were evaluated using the Wilcoxon rank-sum test. All sta-
tistical analyses were conducted using Stata SE 11.1 (StataCorp, College
Station, TX). P values ,0.05 were considered to represent statistical signifi-
cance, and P values #0.10 were considered to represent a trend.
RESULTS
Hyperglycemia and ketosis models. Using the proce-
dures described, substantial hyperglycemia was generated
in the hyperglycemic rat model, with mean blood glucose
concentrations of ;28 mmol/L (Tables 1 and 2). Daily
urine ketone testing after administration of streptozotocin
confirmed absence of ketosis in the hyperglycemic group.
Of note, some rats in the hyperglycemic group had slightly
decreased serum bicarbonate concentrations consistent
with mild renal tubular acidosis (4 of 16 total rats used in
the hyperglycemia studies; serum bicarbonate concentra-
tion range 16–19 mmol/L). This effect was attributed to
renal toxicity of streptozotocin (11). Comparison of mag-
netic resonance measures in hyperglycemic rats with and
without mild renal tubular acidosis (RTA), however, re-
vealed no significant effect of mild RTA on the measures
of interest (data not shown); therefore, results from all
hyperglycemic rats were included in the data reported.
In the ketotic group, blood ketone concentrations ach-
ieved were within a range consistent with moderate ke-
tosis in children with diabetes (Tables 1 and 2). Ketotic
rats had normal blood pH and PCO2 (factors that could
independently affect CBF). Serum insulin concentrations
in both the hyperglycemic group (0.136 0.11 ng/mL, n = 6)
and the ketotic group (1.16 6 0.44 ng/mL, n = 6) were sig-
nificantly lower than in the control group (2.526 1.13 ng/mL,
n = 11; P , 0.01 for hyperglycemia vs. control, P = 0.015
for ketosis vs. control, P = 0.12 for hyperglycemia vs.
ketosis).
Cerebral blood flow. In both the hyperglycemic group
and the ketotic group, there were significant reductions in
CBF in the cerebral cortex in comparison with the control
group (Fig. 1A). In the striatum, there was a trend toward
reduction in CBF in both groups in comparison with con-
trols, but these differences were just short of statistical
significance.
Cerebral water distribution. Using diffusion-weighted
imaging, we observed a significant reduction in ADC in
TABLE 1
Biochemical values in hyperglycemic and ketotic rats versus control rats used for diffusion-weighted and perfusion-weighted imaging
studies
Hyperglycemia Ketosis Control P
n 9 10 —
Glucose (mmol/L) 30.0 (7.8) 6.1 (1.2) 7.9 (1.9) ,0.001 hyperglycemia vs. control, 0.71 ketosis vs. control
bOHB (mmol/L) — 2.1 (0.9) — —
pH 7.37 (0.07) 7.38 (0.04) 7.42 (0.05) 0.08 hyperglycemia vs. control, 0.19 ketosis vs. control
PCO2 (mmHg) 36 (7) 37 (4) 38 (6) 0.58 hyperglycemia vs. control, 0.97 ketosis vs. control
Serum sodium (mmol/L) 142 (6) 140 (4) 141 (4) 0.76 hyperglycemia vs. control, 0.98 ketosis vs. control
Serum chloride (mmol/L) 109 (7) 107 (3) 107 (4) 0.53 hyperglycemia vs. control, 1.0 ketosis vs. control
Serum bicarbonate (mmol/L) 21 (3) 24 (2) 27 (3) ,0.01 hyperglycemia vs. control, 0.12 ketosis vs. control
Data are means (SD) unless otherwise indicated.
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the cerebral cortex, indicating cytotoxic cerebral edema,
in both the hyperglycemic group and the ketotic group
in comparison with the control group (Fig. 1B). In the
striatum, the differences in ADC in comparison with control
values were significant only in the hyperglycemic group.
Cerebral metabolism. Using phosphorus MRS, we detected
significant reductions in brain ratios of PCr to Pi in the
ketotic group and a trend toward reduction in the hy-
perglycemic group in comparison with controls (Fig. 2).
Reductions in brain ATP-to-Pi ratios were significant in
both the hyperglycemic group and the ketotic group in
comparison with controls. Brain intracellular pH was not
significantly different among the three groups. Using proton
MRS, we did not detect any significant differences among
the groups in brain ratios of NAA to Cr or any differences in
brain lactate levels.
DISCUSSION
Cerebral injury caused by DKA shares several common
features with hypoxic-ischemic brain injury. Early descrip-
tions of postmortem findings in children who died of DKA-
related brain injury showed features suggestive of ischemia
(12,13). More recent studies demonstrate that DKA results
in cytotoxic cerebral edema (cell swelling) progressing to
vasogenic cerebral edema (increased extracellular fluid)
during treatment with insulin and saline, a pattern similar
to that observed in ischemia-reperfusion injury (2,7). Fur-
thermore, brain NAA-to-Cr ratios are diminished in DKA
and levels of high-energy phosphates are reduced, similar to
findings in hypoxic-ischemic brain injury (5,14,15).
We have previously demonstrated that CBF is reduced
in DKA, but the cause of this reduction is not fully un-
derstood (6). Cerebral vasoconstriction induced by hypo-
capnia and intravascular volume depletion may account
for some reduction in CBF, but the degree of cerebral in-
jury that occurs in at least some children is greater than
might be expected to result from these conditions alone. It
is possible that other conditions present during DKA might
contribute to reducing CBF. In addition, the decrease in
CBF observed during DKA is modest in comparison with
that typically observed in stroke or other hypoxic-ischemic
conditions, raising the question of whether some other
aspect of DKA might augment the severity of injury caused
by moderate CBF reductions. In the current study, we
demonstrate that both hyperglycemia and ketosis are
associated with reductions in cortical CBF. In addition,
both conditions were associated with reduced brain
levels of high-energy phosphates and reduced ADC val-
ues that could result from disturbances in membrane ion
homeostatic mechanisms. These data suggest that hyper-
glycemia and/or ketosis may increase the vulnerability of
the brain to injury.
Substantial data from previous studies in both humans
and animal models demonstrate an association between
hyperglycemia and worsening of hypoxic-ischemic brain
injury (16–20). In animal studies of stroke, hyperglycemia
is associated with increases in infarct volume, edema for-
mation, neutrophil deposition in ischemic tissue, and lac-
tate accumulation (19,21–23). Hyperglycemia is associated
with impaired vascular endothelial function resulting in
decreased vasodilation (24), as well as with decreased
erythrocyte deformability and alterations in blood flow
properties that might contribute to ischemia (25,26). Re-
duced CBF during hyperglycemia has also previously been
reported in rats (27). Several studies suggest an association
between hyperglycemia and increased morbidity and mor-
tality from ischemic stroke (28–30), and some studies sug-
gest that hyperglycemia may directly cause neuronal injury.
In rats, hyperglycemia (streptozotocin-induced diabetes)
has been found to result in alterations in neuronal structure
and impaired memory (31,32).
The effects of ketosis in the setting of brain injury have
been studied less extensively than the effects of hyper-
glycemia. In one study, acetoacetate was found to increase
production of the vasoconstrictor endothelin-1 in brain
microvascular endothelial cells (33). In addition, elevated
concentrations of acetoacetate have been found to in-
crease erythrocyte viscosity (34). In apparent contrast to
these findings, however, some studies in rodents sug-
gest a neuroprotective effect of ketosis in the setting of
hypoxic-ischemic injury or traumatic injury (35–37). The
mechanism for this apparent protective effect has been
proposed to be related to diminished glycolytically-derived
lactate production as well as decreased free radical gen-
eration (36). Conversely, studies of long-term effects of
ketogenic diets suggest possible detrimental effects on
memory and other cognitive functions in both rats and
humans (38,39). Thus, the effects of ketosis are unclear
and may vary in different physiologic settings. Our results
demonstrate that ketosis (induced by a ketogenic diet)
reduces CBF and decreases brain levels of high-energy
phosphates, which would appear to suggest adverse con-
sequences. In apparent contrast, a study of ketone infusion
in adult rats found an increase in CBF—a finding one
might not predict from our results (40). The reason for
the variation in results between those data and our data
is unclear. The ketone infusion model induces metabolic
alkalosis, and it is possible that alterations in acid-base
balance may have affected CBF. Differences in insulin
TABLE 2
Biochemical values in hyperglycemic and ketotic rats versus control rats used for MRS studies
Hyperglycemia Ketosis Control P
n 7 7 7 —
Glucose (mmol/L) 26.6 (7.4) 6.6 (1.1) 7.8 (1.5) ,0.001 hyperglycemia vs. control, , 0.001 ketosis vs. control
bOHB (mmol/L) — 2.0 (0.6) — —
pH 7.36 (0.08) 7.39 (0.06) 7.42 (0.06) 0.25 hyperglycemia vs. control, 0.65 ketosis vs. control
PCO2 (mmHg) 41 (4) 39 (6) 41 (5) 0.95 hyperglycemia vs. control, 0.89 ketosis vs. control
Serum sodium (mmol/L) 142 (6) 142 (2) 139 (4) 0.45 hyperglycemia vs. control, 0.61 ketosis vs. control
Serum chloride (mmol/L) 108 (7) 107 (2) 106 (4) 0.78 hyperglycemia vs. control, 0.91 ketosis vs. control
Serum bicarbonate (mmol/L) 24 (3) 24 (2) 27 (3) 0.17 hyperglycemia vs. control, 0.17 ketosis vs. control
Data are means (SD) unless otherwise indicated.
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concentrations between the two models might be an-
other possible explanation for the variation in results (see
below).
Our data suggest that both hyperglycemia and ketosis
result in similar alterations in CBF, cerebral water distri-
bution, and cerebral metabolism. Although these states are
dissimilar from a metabolic standpoint, both conditions
are associated with low serum insulin concentrations,
raising the intriguing possibility that the findings may be
related to insulin deficiency rather than direct effects of
hyperglycemia or ketosis. Although the role of insulin in
the brain was previously thought to be minimal, data have
accumulated to suggest that insulin has effects on the
brain, including a role in regulating brain glucose uptake
and metabolism (41–43). Indeed, some effects associated
with hyperglycemia are more likely caused by low insulin
levels than by the hyperglycemia per se. In one study, di-
abetic rats were shown to have increased infarct volumes
after ischemia/reperfusion injury compared with control
rats (44). Differences between the groups were eliminated
by insulin treatment; however, treatment with TDZD-8
(a selective inhibitor of glycogen synthase kinase-b) to
replicate one important pharmacological effect of insulin
resulted in almost identical benefits despite persistence
of hyperglycemia. Similarly, another study demonstrated
reduced ADC values in diabetic rats (45). These values were
normalized with insulin treatment, but treatment with IGF-1,
resulting in insulin receptor activation, was found to have
similar effects on ADC despite persistence of hyperglycemia.
Recent data support a neuroprotective role for insulin
and suggest that lack of insulin in the brain, or absence
of insulin effect, might cause or augment cerebral injury
(46,47). Insulin-mediated signaling pathways have been
hypothesized to be involved in regulation of neuronal
survival, synaptic plasticity, learning, and memory func-
tion (46–48). Impairment of insulin receptor signaling in
the brain has been proposed to contribute to age-related
cognitive declines and has been suggested to play a role
in several neurodegenerative disorders (46–49). Some in-
vestigators have hypothesized that insulin might exert
neuroprotective effects under pathological conditions via
stimulation of glucose metabolism resulting in increased
brain levels of high-energy phosphates (47,50). Our
results are of particular interest in this regard, as both
low-insulin states evaluated in our study resulted in reduc-
tions in brain high-energy phosphates. In addition, insulin
has been shown to enhance vasodilation and blood flow
(24). Again, low insulin levels in both conditions in our
study might be one possible explanation for the observed
reductions in CBF.
The current study has some limitations. The level of
ketosis achieved in the ketotic rats was lower than typi-
cally observed in children with DKA. Although greater
ketosis could have been achieved with an intravenous
ketone infusion, the fluid volume required for this infusion
would cause changes in circulatory volume and therefore
confounding effects on measures of CBF. In addition,
higher ketone concentrations could result in metabolic
acidosis with compensatory hypocapnia causing alterations
in CBF. We therefore opted to evaluate more moderate
ketosis and to use dietary manipulations to avoid altering
circulatory volume. It is possible that the effects of ketosis
might have been greater if higher concentrations of ketone
bodies could have been achieved. In addition, several rats in
the hyperglycemic group had mild metabolic acidosis, likely
reflecting renal tubular acidosis resulting from nephrotoxic
effects of streptozotocin treatment (11). We did not, how-
ever, detect any significant differences in magnetic reso-
nance measures in hyperglycemic rats with or without RTA,
and the degree of acidosis in all rats was mild and unlikely
to cause any substantial physiological alterations.
In summary, our results suggest that hyperglycemia and
ketosis both result in declines in CBF, reductions in ce-
rebral high-energy phosphate concentrations, and brain
cell swelling. The reductions in CBF resulting from hy-
perglycemia and/or ketosis help to explain the occurrence
of cerebral hypoperfusion during DKA that appears to be
greater than would be expected to result from hypocapnia
and circulatory volume depletion alone. Furthermore, the
apparently adverse effects of these conditions on cerebral
metabolism might cause the brain to be more vulnerable to
injury during modest hypoperfusion associated with DKA.
Finally, the similarity in cerebral effects of hyperglycemia
and ketosis raises the intriguing possibility that low insulin
concentrations might be a predicating factor common to
FIG. 1. A: CBF in hyperglycemic and ketotic rats in comparison with
control rats measured using arterial spin labeling (means 6 SE for 10
ketotic, 10 control, and 9 hyperglycemic rats). Cortex: P = 0.03 hyper-
glycemic vs. control, P = 0.02 ketotic vs. control. Striatum: P = 0.06
hyperglycemic vs. control, P = 0.07 ketotic vs. control. B: Apparent
diffusion coefficients in hyperglycemic rats and ketotic rats in com-
parison with control rats (means 6 SE for 10 ketotic and 10 control
rats and 9 hyperglycemic rats). Cortex: P = 0.004 hyperglycemic vs.
control, P = 0.012 ketotic vs. control. Striatum: P = 0.019 hyperglycemic
vs. control, P = 0.46 ketotic vs. control.
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FIG. 2. Cerebral metabolites in hyperglycemic rats and ketotic rats in comparison with control rats measured using proton and phosphorus
MRS (means 6 SE; n = 7 for all groups). A: PCr-to-Pi ratio. B: ATP-to-Pi ratio. C: Intracellular (Int) pH. D: Lactate (Lac)-to-Cr ratio. E: NAA-
to-Cr ratio.
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both protocols or conditions. This hypothesis will require
further investigation in future studies.
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